tirofiban has been researched along with Arrhythmia in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, R; Tang, X; Zhang, T | 1 |
| Chen, LY; Hsin, HT; Liao, PC; Lin, PC; Wu, CF | 1 |
| Bolognese, L; Bramucci, E; Campo, G; Colangelo, S; Corrada, E; De Cesare, N; E Rodriguez, A; Ferrante, G; Ferrari, R; Moreno, R; Nazzaro, MS; Pasquetto, G; Piva, T; Prati, F; Presbitero, P; Sheiban, I; Valgimigli, M; Vassanelli, C | 1 |
| Baroni, M; Musumeci, G; Rossini, R | 1 |
| Böhm, M; Fries, R | 1 |
2 review(s) available for tirofiban and Arrhythmia
| Article | Year |
|---|---|
GP IIb/IIIa inhibitors for STEMI: still the gold standard or an old survivor?
Topics: Abciximab; Animals; Antibodies, Monoclonal; Arrhythmias, Cardiac; Eptifibatide; Evidence-Based Medicine; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2012 |
[Update cardiology 2001/2002-part II. From unstable coronary syndrome to terminal heart failure].
Topics: Abciximab; Acute Disease; Adrenergic beta-Antagonists; Angina, Unstable; Antibodies, Monoclonal; Anticholesteremic Agents; Arrhythmias, Cardiac; Aspirin; Atorvastatin; Clopidogrel; Defibrillators, Implantable; Double-Blind Method; Fibrinolytic Agents; Heart Failure; Heart Septal Defects, Atrial; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin Fab Fragments; Myocardial Infarction; Placebos; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Regeneration; Risk Factors; Syndrome; Ticlopidine; Time Factors; Tirofiban; Tyrosine | 2003 |
3 trial(s) available for tirofiban and Arrhythmia
| Article | Year |
|---|---|
Comparison of intracoronary versus intravenous tirofiban in acute ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.
Topics: Anterior Wall Myocardial Infarction; Arrhythmias, Cardiac; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Tirofiban; Treatment Outcome; Tyrosine | 2022 |
Upstream tirofiban reduces reperfusion cardiac arrhythmias in patients of acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Arrhythmias, Cardiac; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion Injury; Tirofiban; Tyrosine; Young Adult | 2011 |
Sex-specific benefits of sirolimus-eluting stent on long-term outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: insights from the Multicenter Evaluation of Single High-Dose Bolus Tirofiban
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Arrhythmias, Cardiac; Drug-Eluting Stents; Female; Humans; Immunoglobulin Fab Fragments; Immunosuppressive Agents; Italy; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Sex Factors; Sirolimus; Tirofiban; Tyrosine | 2012 |